Simon Correa1, Jessy Korina Pena-Esparragoza2, Katherine M Scovner3, Sushrut S Waikar4, Finnian R Mc Causland3. 1. Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: scorreagaviria@bwh.harvard.edu. 2. Nephrology Section, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. 3. Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. 4. Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; Renal Section, Department of Medicine, Boston University Medical Center, Boston, MA.
Abstract
BACKGROUND: Myeloperoxidase (MPO) catalyzes the formation of reactive nitrogen species and levels are elevated in patients with chronic kidney disease (CKD). Although increased oxidative stress and inflammation are associated with progression of CKD and cardiovascular disease (CVD), relationships between MPO concentration, CKD progression, CVD, and death remain unclear. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 3,872 participants from the Chronic Renal Insufficiency Cohort (CRIC) who had MPO measured at baseline. EXPOSURE: Baseline MPO concentration. OUTCOMES: CKD progression (kidney transplantation, dialysis initiation, or 50% decline in baseline estimated glomerular filtration rate [eGFR] and eGFR≤15mL/min/1.73m2), CVD (heart failure, myocardial infarction, or stroke), and death. ANALYTICAL APPROACH: Cox proportional hazards models. RESULTS: In adjusted analyses, higher MPO level (per 1-SD increase in log-transformed MPO) was associated with 10% higher risk for CKD progression (adjusted HR, 1.10; 95% CI, 1.01-1.19; P=0.03), 12% higher risk for CVD (adjusted HR, 1.12; 95% CI, 1.03-1.22; P<0.01), and 13% increased risk for death (adjusted HR, 1.13; 95% CI, 1.04-1.22; P<0.01). There was evidence for effect modification of the association of MPO level with CKD progression by baseline eGFR (P interaction=0.02), but not for CVD (P interaction=0.2) or death (P interaction=0.1). In stratified analyses, MPO level (per 1-SD increase in log-transformed MPO) was associated with greater risk for CKD progression among participants with eGFR>45mL/min/1.73m2 (adjusted HR, 1.23; 95% CI, 1.03-1.46; P=0.02) compared with those with eGFR≤45mL/min/1.73m2 (adjusted HR, 1.10; 95% CI, 1.02-1.20; P=0.02). The association of MPO level with CVD and death was no longer significant after adjustment for cardiac biomarkers. LIMITATIONS: Potential residual confounding, lack of repeated measurements of MPO. CONCLUSIONS: Higher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
BACKGROUND: Myeloperoxidase (MPO) catalyzes the formation of reactive nitrogen species and levels are elevated in patients with chronic kidney disease (CKD). Although increased oxidative stress and inflammation are associated with progression of CKD and cardiovascular disease (CVD), relationships between MPO concentration, CKD progression, CVD, and death remain unclear. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 3,872 participants from the Chronic Renal Insufficiency Cohort (CRIC) who had MPO measured at baseline. EXPOSURE: Baseline MPO concentration. OUTCOMES: CKD progression (kidney transplantation, dialysis initiation, or 50% decline in baseline estimated glomerular filtration rate [eGFR] and eGFR≤15mL/min/1.73m2), CVD (heart failure, myocardial infarction, or stroke), and death. ANALYTICAL APPROACH: Cox proportional hazards models. RESULTS: In adjusted analyses, higher MPO level (per 1-SD increase in log-transformed MPO) was associated with 10% higher risk for CKD progression (adjusted HR, 1.10; 95% CI, 1.01-1.19; P=0.03), 12% higher risk for CVD (adjusted HR, 1.12; 95% CI, 1.03-1.22; P<0.01), and 13% increased risk for death (adjusted HR, 1.13; 95% CI, 1.04-1.22; P<0.01). There was evidence for effect modification of the association of MPO level with CKD progression by baseline eGFR (P interaction=0.02), but not for CVD (P interaction=0.2) or death (P interaction=0.1). In stratified analyses, MPO level (per 1-SD increase in log-transformed MPO) was associated with greater risk for CKD progression among participants with eGFR>45mL/min/1.73m2 (adjusted HR, 1.23; 95% CI, 1.03-1.46; P=0.02) compared with those with eGFR≤45mL/min/1.73m2 (adjusted HR, 1.10; 95% CI, 1.02-1.20; P=0.02). The association of MPO level with CVD and death was no longer significant after adjustment for cardiac biomarkers. LIMITATIONS: Potential residual confounding, lack of repeated measurements of MPO. CONCLUSIONS: Higher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
Authors: Zinah Zwaini; Meeta Patel; Cordula Stover; John Dormer; Michael L Nicholson; Sarah A Hosgood; Bin Yang Journal: Medicina (Kaunas) Date: 2020-06-26 Impact factor: 2.430
Authors: Ype de Jong; Edouard L Fu; Merel van Diepen; Marco Trevisan; Karolina Szummer; Friedo W Dekker; Juan J Carrero; Gurbey Ocak Journal: Eur Heart J Date: 2021-04-14 Impact factor: 29.983
Authors: Tord Inghardt; Thomas Antonsson; Cecilia Ericsson; Daniel Hovdal; Petra Johannesson; Carina Johansson; Ulrik Jurva; Johan Kajanus; Bengt Kull; Erik Michaëlsson; Anna Pettersen; Tove Sjögren; Henrik Sörensen; Kristina Westerlund; Eva-Lotte Lindstedt Journal: J Med Chem Date: 2022-08-25 Impact factor: 8.039
Authors: Alexander Hof; Simon Geißen; Kezia Singgih; Martin Mollenhauer; Holger Winkels; Thomas Benzing; Stephan Baldus; Friedrich Felix Hoyer Journal: Basic Res Cardiol Date: 2022-07-27 Impact factor: 12.416
Authors: James Tollitt; Stuart M Allan; Rajkumar Chinnadurai; Aghogho Odudu; Margaret Hoadley; Craig Smith; Philip A Kalra Journal: BMC Nephrol Date: 2022-01-18 Impact factor: 2.388